Assessing the RESILIENT SMA Trial Results for Taldefgrobep Alfa in Spinal Muscular Atrophy from Biohaven Pharmaceuticals

Executed on:Feb 7, 2025 9:00 AM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: Mayo ClinicClinical Neurologist at the Mayo Clinic with PhD in Neuroscience. Additionally certified in neuromuscular, autonomic and pain medicine.
Manages 8 patients with Spinal Muscular Atrophy.
Research focuses on autonomic disorders, specifically pure autonomic failure, autoimmune autonomic neuropathies, postural tachycardia syndrome and multiple system atrophy with a goal of characterizing and describing the natural history of these disorders, assessing quality of life for patients with these conditions, identifying predictors of good versus poor outcome and conducting therapeutic trials.

Interview Goal

This interview examines the findings from the RESILIENT Phase 3 trial of taldefgrobep alfa in Spinal Muscular Atrophy (SMA). Discussion topics include motor function improvements, subgroup analyses, body composition changes, and the implications for future development in SMA and obesity.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.